IL2 and type 1 diabetes mellitus: These in vitro data are compatible with the in vivo observations that IL-2 administration resulted in autoimmunity or augmented immune responsiveness [24,25,26,27], but they cannot explain an opposing observation such as IL-2 immunotherapy preventing and reversing IDDM in NOD mouse model [28].